• Vaccine Name: Lymphocytic Chloriomeningitis Virus Vaccine rLCMV-OVA
• Target Pathogen: Lymphocytic choriomeningitis virus
• Target Disease: Lymphocytic choriomeningitis
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Antigen: OVA (Krolik et al., 2021)
• Immunization Route: Intravenous injection (i.v.)
• Description: Ifnar-/- vaccinated with propagation-deficient rLCMV vector expressing ovalbumin are protected from a challenge with the aggressive LCMV Arm and LCMV Clone 13. (Krolik et al., 2021)

Mouse Response

• Vaccination Protocol: Age and sex-matched animals were vaccinated with 1x10^6 pfu of rLCMV-OVA. Wt or Ifnar-/- mice were used. (Krolik et al., 2021)
• Immune Response: In wt mice, induction of viral NP396 specific CD8+ T cells peaked at day eight and two weeks after vaccination for OVA257. In Ifnar-/-, T cell induction was delayed but reached equally high frequencies of antigen-specific CD8+ T cells by day 16 for the nucleoprotein and by day 30 for the vaccine antigen ovalbumin. (Krolik et al., 2021)
• Challenge Protocol: rLCMV-immunized wt or Ifnar-/- mice were challenged with low dose (200 pfu) or high dose (1x10^5 pfu) LCMV Arm (LCMV strain Armstrong). (Krolik et al., 2021)
• Efficacy: Immunized wt mice showed a sterile protection even after a high dose challenge. Ifnar-/- contained a low dose LCMV Arm challenge. Immunized Ifnar-/- receiving a high dose of LCMV Arm were partially protected, i.e. spreading of virus was pre- vented as virus remained below the detection limit in the liver. (Krolik et al., 2021)

Mouse Response

• Vaccination Protocol: Age and sex-matched animals were vaccinated with 1x10^6 pfu of rLCMV-OVA. Wt or Ifnar-/- mice were used. (Krolik et al., 2021)
• Immune Response: In wt mice, induction of viral NP396 specific CD8+ T cells peaked at day eight and two weeks after vaccination for OVA257. In Ifnar-/-, T cell induction was delayed but reached equally high frequencies of antigen-specific CD8+ T cells by day 16 for the nucleoprotein and by day 30 for the vaccine antigen ovalbumin. (Krolik et al., 2021)
• Challenge Protocol: rLCMV immunized wt and Ifnar-/- mice were infected with 200 or 1x10^5 pfu of LCMV Cl13. (Krolik et al., 2021)
• Efficacy: Vaccinated wt mice controlled viral dissemination. rLCMV vaccinated Ifnar-/- showed a significantly reduced viral titer compared to unvaccinated controls in a low dose challenge with LCMV Cl13. rLCMV vectors can protect Ifnar-/- from a low dose challenge with the highly aggressive LCMV Cl13. (Krolik et al., 2021)